{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134767","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.491976+00:00","generated_at":"2026-06-02T06:56:41.683140+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensei Biotherapeutics Q1 net loss narrows to $8M; SNS-101 Phase 1 dose escalation complete, no DLTs","bullets":["Net loss of $8.0M for Q1 2024 vs $10.2M in Q1 2023; R&D spend $4.9M, G&A $3.8M.","Cash, cash equivalents and marketable securities $58.1M at March 31, 2024; runway into Q4 2025.","SNS-101 Phase 1/2 dose escalation completed: 16 patients monotherapy, 18 combination; no DLTs observed.","Topline data at ASCO 2024; dose expansion enrolling; end-of-Phase 1 FDA meeting expected by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134767","json":"https://secwatch.observer/filing/0001193125-24-134767.json","markdown":"https://secwatch.observer/filing/0001193125-24-134767.md","text":"https://secwatch.observer/filing/0001193125-24-134767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/0001193125-24-134767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/d836832d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:56:41.683140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e96438c8a8240608b0522cfea92fdb3899a480cb","claim":"Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $8.0 million for the quarter ended March 31, 2024.","evidence_excerpt":"Net loss was $8.0 million for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524134767/0001193125-24-134767-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $8.0 million for the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}